drugset / Trial / NCT03535415
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation
Phase 3
Unknown
68 enrolled
Changchun GeneScience Pharmaceutical Co., Ltd.
Beijing Children's Hospital · collabChildren's Hospital of Chongqing Medical University · collabChildren's Hospital of Fudan University · collabChildren's Hospital of The Capital Institute of Pediatrics · collabFuzhou General Hospital · collabHuazhong University of Science and Technology · collabPeking University First Hospital · collabShanghai Children's Hospital · collabShengjing Hospital · collabThe Children's Hospital of Zhejiang University School of Medicine · collabThe First Affiliated Hospital of Zhengzhou University · collabXinhua Hospital, Shanghai Jiao Tong University School of Medicine · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy and safety of recombinant human growth hormone injection in short stature children due to chronic kidney disease before transplantation.
Timeline
- Start
- 2018-06-25
- Primary completion
- 2020-09
- Completion
- 2021-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Somatropin | Protein / enzyme biologic | 0.05 mg/kg | Subcutaneous |
Indications
No indication recorded.